Step 1 topics → Hematology and Oncology → Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia (ALL)

USMLE Step 1 trap: Inverts the prognostic hierarchy of ALL translocations, assigning worst prognosis to t(12;21) instead of t(9;22). t(9;22) BCR-ABL (Philadelphia chromosome) carries the worst prognosis in ALL, while t(12;21) TEL-AML1 carries the best prognosis.

Acute Lymphoblastic Leukemia (ALL) is a malignancy of immature lymphoid precursors — either B-cell or T-cell lineage — that accumulates in bone marrow and peripheral blood. It's the most common childhood cancer, and USMLE Step 1 tests it from multiple angles: pure recall of markers and translocations, clinical scenario interpretation, and application questions matching a translocation to prognosis or treatment. The most common translocation error: students confuse t(12;21) and t(9;22). The Philadelphia chromosome t(9;22) carries the worst prognosis in ALL and requires adding a TKI; t(12;21) TEL-AML1 is the most common pediatric ALL translocation and carries the best prognosis. Getting these swapped means getting any prognosis or management question on this topic wrong. The distinction between B-ALL and T-ALL also matters — T-ALL presents in adolescent males with a mediastinal mass, which the exam loves as a clinical vignette.

The immunophenotype questions are where students lose points. TdT and CD10 are the marquee markers for ALL, but students frequently flip TdT — attributing it to AML instead. This is a critical error because TdT is one of the key distinguishing features of ALL over AML on the exam. CD10 (the CALLA antigen) is specifically associated with B-ALL. Getting the lineage markers right (CD19/CD20 for B-ALL, CD3/CD7 for T-ALL) is also fair game for USMLE Step 1.

Cytogenetics is the other high-yield area where students consistently make mistakes. There are two translocations you must know cold and keep straight: t(12;21) TEL-AML1, which is the most common translocation in pediatric B-ALL and carries the best prognosis, versus t(9;22) BCR-ABL (the Philadelphia chromosome), which carries the worst prognosis and changes management by requiring addition of a tyrosine kinase inhibitor. Students frequently invert this hierarchy or misapply imatinib to the wrong translocation — both errors show up on board questions.

From real student decks
73%have cards covering this topic
54%have mature cards

Common misconceptions

Common mistake
Wrong: T(12;21) TEL-AML1 carries the worst prognosis in ALL.
Right: t(9;22) BCR-ABL (Philadelphia chromosome) carries the worst prognosis in ALL, while t(12;21) TEL-AML1 carries the best prognosis.
Students confuse t(12;21) and t(9;22) because both are high-yield ALL translocations tested together. The key is to anchor on BCR-ABL: the Philadelphia chromosome t(9;22) is the same translocation that defines CML and always signals aggressive disease — in ALL it carries the worst prognosis. Meanwhile t(12;21) TEL-AML1 is the most common translocation in pediatric B-ALL and is associated with a favorable outcome. Think of it this way: Philadelphia = poor across the board (ALL and CML), t(12;21) = the 'good' pediatric translocation.
Common mistake
Wrong: Imatinib (TKI) is added to chemotherapy for ALL patients with t(12;21).
Right: Imatinib or other BCR-ABL tyrosine kinase inhibitors are added to chemotherapy only for Philadelphia chromosome-positive ALL (t(9;22)), not for t(12;21).
Imatinib and other BCR-ABL tyrosine kinase inhibitors work by targeting the specific fusion protein produced by the t(9;22) translocation — they have no mechanism of action relevant to t(12;21), which produces a completely different fusion protein (TEL-AML1). Adding a TKI only makes sense when BCR-ABL kinase is present. If a vignette describes Philadelphia chromosome-positive ALL, TKI is added; for any other translocation, it is not.
Common mistake
Wrong: TdT positivity is specific to AML and helps distinguish it from ALL.
Right: TdT (terminal deoxynucleotidyl transferase) is a marker of immature lymphoblasts and is positive in ALL (and lymphoblastic lymphoma), not in AML.
TdT (terminal deoxynucleotidyl transferase) is an enzyme expressed in immature lymphoid precursors — lymphoblasts. It is a hallmark of ALL and lymphoblastic lymphoma, not AML. AML is identified by myeloperoxidase (MPO) positivity and Auer rods. A helpful mental model: TdT marks 'immature lymphoid cells trying to rearrange their receptor genes,' which is a lymphoid-specific process. On USMLE Step 1, TdT positivity in a leukemia vignette points to ALL, not AML.
Common mistake
Gap: Misses the rationale for mandatory CNS prophylaxis in ALL treatment due to CNS sanctuary site
CNS prophylaxis (intrathecal chemotherapy or cranial radiation) is required in ALL because lymphoblasts can sanctuary in the CNS, which is poorly penetrated by systemic chemotherapy.
The blood-brain barrier acts as a 'sanctuary site' — systemic chemotherapy doesn't penetrate the CNS well enough to kill lymphoblasts hiding there. Without CNS-directed treatment, blasts that survive in the CNS will repopulate and cause relapse. This is why all ALL patients receive intrathecal methotrexate (injected directly into the CSF) as a mandatory component of therapy, regardless of whether CNS disease is detected at diagnosis. Understanding this rationale helps you answer 'why' questions, not just memorize the protocol.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the demographics: ALL peaks in children ages 2–5, and you should be able to recognize the classic presentation — fatigue, bone pain, lymphadenopathy, and hepatosplenomegaly — in a pediatric vignette.
  2. Know that T-ALL specifically presents in adolescent males with an anterior mediastinal mass, which can cause SVC syndrome or airway compression — this is a distinct clinical picture from B-ALL.
  3. Identify the immunophenotype of ALL: TdT-positive (lymphoblast marker), CD10-positive in B-ALL, and distinguish B-ALL (CD19/CD20) from T-ALL (CD3/CD7) — and know that TdT distinguishes ALL from AML.
  4. Know the two key translocations and their clinical implications: t(12;21) TEL-AML1 = most common in pediatric ALL, best prognosis; t(9;22) BCR-ABL = Philadelphia chromosome, worst prognosis, requires addition of imatinib to chemotherapy.
  5. Understand ALL management: induction, consolidation, and maintenance phases, plus mandatory CNS prophylaxis with intrathecal chemotherapy (and sometimes cranial radiation) because the CNS is a sanctuary site poorly penetrated by systemic chemotherapy.
  6. Know the outcome difference by age: children with ALL have excellent cure rates (~85–90%), while adults have significantly worse prognosis — this is a classic board contrast.

Can you avoid these mistakes?

A 4-year-old boy presents with fatigue, pallor, and diffuse bone pain. CBC shows lymphoblasts. Flow cytometry is TdT-positive, CD10-positive, CD19-positive. Cytogenetics reveal t(12;21). What is the prognosis, and does this patient require a tyrosine kinase inhibitor?
A 16-year-old male presents with facial swelling, dyspnea, and an anterior mediastinal mass on chest X-ray. Biopsy shows TdT-positive blasts expressing CD3 and CD7. What is the diagnosis, and how does this differ from the typical ALL presentation in a 3-year-old?
You are asked to distinguish ALL from AML on a lab question. Which markers favor ALL, and which favor AML? Be specific about TdT, MPO, and CD markers.
A 35-year-old woman is diagnosed with ALL and cytogenetics show t(9;22). How does this change her treatment compared to a patient with t(12;21), and what is the prognostic implication of each translocation?

Related topics

Leukemia vs Lymphoma Framework Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →